Original Report

Feasibility of implementing a community-based randomized trial of yoga for women undergoing chemotherapy for breast cancer


 

Background Treatment-related symptoms and decreased health-related quality of life (HRQoL) frequently occur during chemotherapy for breast cancer. Although research findings suggest that yoga can reduce symptoms and improve HRQoL after treatment, potential benefits of yoga during chemotherapy have received minimal attention.

Objective To estimate accrual, adherence, study retention, and preliminary efficacy of a yoga intervention compared with an active control group for breast cancer patients during chemotherapy.

Methods Women with stage I-III breast cancer were recruited from 3 community cancer clinics and randomized to 10 weeks of gentle yoga or wellness education. Depressive symptoms, fatigue, sleep, and HRQoL were assessed at baseline, mid-intervention (Week 5), and after intervention (Week 10).

Results 40 women aged 29-83 years (median, 48 years; 88% white) were randomized to yoga (n = 22) or wellness education (n = 18). The groups did not differ significantly on baseline characteristics, adherence, or study retention. Participant feedback was positive and comparable between groups. Meaningful within-group differences were identified for sleep adequacy and quantity in yoga participants and for somnolence in wellness-education participants.

Limitations Small sample size and lack of a usual-care control group.

Conclusions This study established feasibility of a community-based randomized trial of yoga and an active comparison group for women undergoing chemotherapy for breast cancer. Preliminary efficacy estimates suggest that yoga improves sleep adequacy. Symptom severity and interference remained stable during chemotherapy for the yoga group and showed a trend toward increasing in the control group. The study highlighted obstacles to multisite yoga research during cancer treatment.

Funding/sponsorship National Cancer Institute (3U10 CA081851, PI: Shaw; R25 CA122061, PI: Avis); Translational Science Institute, Wake Forest School of Medicine

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Does a family history of both breast and prostate cancer (vs breast only) put a woman at greater risk for future breast cancer?
Breast Cancer ICYMI
False-positive mammograms cost $2.8 billion a year
Breast Cancer ICYMI
Type, location of BRCA mutations influence risk
Breast Cancer ICYMI
Neoadjuvant therapy facilitates breast conservation
Breast Cancer ICYMI
Sleep disorders in patients with cancer
Breast Cancer ICYMI
Task Force: Start biennial mammograms at age 50
Breast Cancer ICYMI
Class of 2015: New drugs projected to earn billions and billions
Breast Cancer ICYMI
PD-L1 blockade breaks through triple-negative breast cancer
Breast Cancer ICYMI
Managing change in oncology
Breast Cancer ICYMI
Palonosetron and netupitant for prevention of chemotherapy-induced nausea and vomiting
Breast Cancer ICYMI